Union MoS Anupriya Patel addresses 19th International Conference of Drug Regulatory Authorities

New Delhi [India], October 16 (ANI): At 19th International Conference of Drug Regulatory Authorities (ICDRA) INDIA-2024, MoS Health Anupriya Patel on Wednesday said that new rules and regulatory introduced to bring medical advancement to match the expectation at global level.

“India has the opportunity to host the 19th international conference of drug regulators this time. We have participants from 120 member states. During this conference, various technical sessions are being organised where the theme of smart regulation is the guiding force. All these international regulators are delibrating on various aspects of bringing about harmonisation in regulations concerning drugs, vaccines and medical equipment,” she said.

“New rules and regulatory procedures introduced in India such as New Drugs and Clinical Trial Rules 2019 and Medical Device Rules 2017 have promoted scientific and ethical research at par with global expectation and international practices. ICDRA is crucial in sharing knowledge, building partnerships, and working in harmonisation to ensure safe and effective medicines for everyone,” she added.

The Union Minister further said that securing the membership of IMRDF & PDG are major milestone in Indian medical research and standards.

“Gaining of affiliate membership of IMRDF and recognition of Indian Pharmacopoeia by the Pharmacopoeial Discussion Group are milestones marking the harmonisation and recognition of regulatory standards,” she said.

Meanwhile, Dr VK Paul, Member, NITI Aayog said, “Quality medicines improve the quality of life, human productivity as well as the way of life. This year’s ICDRA is crucial for its commitment to strengthen regulatory environment worldwide, especially coming after the Covid-19 pandemic.”

He further said “India licenced 8 vaccines for use during the pandemic through a proper regulatory process. Different variants of vaccines including mRNA, DNA, nasal vaccines etc were available for a fraction of the cost of other vaccines that were available in the world.”